HighTower Advisors
TAK icon

HighTower Advisors’s Takeda Pharmaceutical TAK Stock Holding History

HighTower Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 3669
2021
Q4 		$1K Buy
+10
New +$140 ﹤0.01% 3268

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HighTower Advisors's TAK Position: Q2 2026 in Review

HighTower Advisors reduced its Takeda Pharmaceutical (TAK) stake by 7.4% in Q2 2026, selling an estimated $126K and leaving 95,466 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

HighTower Advisors first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.91M in Q1 2026. 379 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • HighTower Advisors held 95,466 shares of Takeda Pharmaceutical worth $1.53M as of Q2 2026.
  • HighTower Advisors sold 7,616 Takeda Pharmaceutical shares in Q2 2026, an estimated $126K.
  • Takeda Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1955 holding.
  • HighTower Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • HighTower Advisors's Takeda Pharmaceutical position peaked at $1.91M in Q1 2026.
  • 379 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.